ReviewNature reviews. Microbiology2014
Novel vaccine vectors for HIV-1.
Review in Nature reviews. Microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).Lancet (London, England) · 2018Trial
- Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).PloS one · 2016Trial
- Research Progress of Microneedles in Vaccine Delivery.Current medicinal chemistry · 2026Review
- Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review.Infection and drug resistance · 2025Review
- Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.Journal of virology · 2022Review
- COVID-19 vaccination and HIV-1 acquisition - Authors' reply.Lancet (London, England) · 2022Article
- Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination.Journal of virology · 2021Article
- Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.PLoS pathogens · 2021Article
- Lentiviral vector induces high-quality memory T cells via dendritic cells transduction.Communications biology · 2021Article
- Novel approaches for vaccine development.Cell · 2021Review
- HIV mRNA Vaccines-Progress and Future Paths.Vaccines · 2021Review
- Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Oral Vaccination Approaches for Anti-SHIV Immunity.Frontiers in immunology · 2021Article
- RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines.Scientific reports · 2020Article
- Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.Vaccine · 2019Article
- Review
- A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.Science translational medicine · 2019Article
- Article
- Defining Kinetic Properties of HIV-Specific CD8⁺ T-Cell Responses in Acute Infection.Microorganisms · 2019Article
- Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy.Journal of biological research (Thessalonike, Greece) · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
The ultimate solution to the global HIV-1 epidemic will probably require the development of a safe and effective vaccine. Multiple vaccine platforms have been evaluated in preclinical and clinical trials, but given the disappointing results of clinical efficacy studies so far, novel vaccine approaches are needed. In this Opinion article, we discuss the scientific basis and clinical potential of novel adenovirus and cytomegalovirus vaccine vectors for HIV-1 as two contrasting but potentially complementary vector approaches. Both of these vector platforms have demonstrated partial protection against stringent simian immunodeficiency virus challenges in rhesus monkeys using different immunological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.